Kalaris Therapeutics Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLRS research report →
Companykalaristx.com
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
- CEO
- Andrew Oxtoby
- IPO
- 2020
- Employees
- 14
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $90.33M
- P/E
- -2.60
- P/S
- 0.00
- P/B
- 1.67
- EV/EBITDA
- -1.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.78%
- ROIC
- -46.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-43,438,000 · 26.09%
- EPS
- $-2.85 · 75.70%
- Op Income
- $-46,152,000
- FCF YoY
- 36.23%
Performance & Tape
- 52W High
- $11.88
- 52W Low
- $2.14
- 50D MA
- $6.20
- 200D MA
- $6.48
- Beta
- 0.15
- Avg Volume
- 77.73K
Get TickerSpark's AI analysis on KLRS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 19, 26 | Hagen Brett R | other | 60,800 |
| Mar 20, 26 | Hagen Brett R | sell | 1,915 |
| Mar 19, 26 | Oxtoby Andrew | other | 222,000 |
| Mar 19, 26 | Gall Matthew | other | 95,000 |
| Mar 19, 26 | Feinsod Matthew | other | 135,000 |
| Dec 18, 25 | AKKARAJU SRINIVAS | buy | 479,847 |
| Dec 22, 25 | AKKARAJU SRINIVAS | other | 1,500,000 |
| Nov 3, 25 | Gall Matthew | other | 235,000 |
| Nov 3, 25 | Gall Matthew | other | 0 |
| Apr 10, 25 | Hagen Brett R | other | 50,262 |
Our KLRS Coverage
We haven't published any research on KLRS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KLRS Report →